MenaINVIsoform Expression in Human Invasive Ductal Carcinomas of the Breast Correlates with Tumor Microenvironment of Metastatsis (TMEM) Score; a Pilot Study Indicating the Potential Use of MenaINV/11a Ratio as a Predictor of Distant Metastases.

The trial and evaluation of mobile health (mHealth) applications in society is necessary to explore the potential use and benefits of the solution post-trial. In recent years, there is a proliferation of mHealth projects developed and tested in the continent of Africa. The complexity of these projects means that there are typically many stakeholders who are integral to the success of the project. Yet, extant research falls short of capturing the motivations and expectations of multiple key stakeholders (i.e. direct and indirect users) in a single study towards participating in mHealth pilots. To address this gap in research a conceptual model is proposed and examined to explore the impact of motivations and expectations on both community health workers' (direct users) and caregivers' (indirect users) decision to participate in mHealth pilot studies. Findings reveal that both motivations and expectations positively impact decision making, i.e. their decision to participate in the study, with no significant differences emerging between these two groups of stakeholders.

Download Full-text

Potential use of oxygen and carbon isotopic composition of otoliths to identify migratory and non‐migratory stocks of the New Zealand common smelt: A pilot study

New Zealand Journal of Marine and Freshwater Research ◽

10.1080/00288330.1989.9516370 ◽

1989 ◽

Vol 23 (3) ◽

pp. 337-344 ◽

Cited By ~ 45

Author(s):

Campbell S. Nelson ◽

Thomas G. Northcote ◽

Chris H. Hendy

Keyword(s):

New Zealand ◽

Pilot Study ◽

Isotopic Composition ◽

Carbon Isotopic Composition ◽

Carbon Isotopic ◽

Potential Use

Download Full-text

Tumor Microenvironment-Dependent 18F-FDG, 18F-Fluorothymidine, and 18F-Misonidazole Uptake: A Pilot Study in Mouse Models of Human Non-Small Cell Lung Cancer

Journal of Nuclear Medicine ◽

10.2967/jnumed.111.098087 ◽

2012 ◽

Vol 53 (8) ◽

pp. 1262-1268 ◽

Cited By ~ 32

Author(s):

T. Huang ◽

A. C. Civelek ◽

J. Li ◽

H. Jiang ◽

C. K. Ng ◽

...

Keyword(s):

Lung Cancer ◽

Pilot Study ◽

Tumor Microenvironment ◽

Small Cell Lung Cancer ◽

Mouse Models ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

18F Fdg

Download Full-text

Pilot Study of Early Start of Chemotherapy after Resection of Primary Colorectal Cancer with Distant Metastases (Pearl Star 01)

Annals of Oncology ◽

10.1016/s0923-7534(20)32188-8 ◽

2012 ◽

Vol 23 ◽

pp. xi83

Author(s):

Y. Yoshida ◽

S. Hoshino ◽

T. Miyake ◽

N. Aisu ◽

S. Tanimura ◽

...

Keyword(s):

Colorectal Cancer ◽

Pilot Study ◽

Distant Metastases ◽

Primary Colorectal Cancer ◽

Early Start

Download Full-text

Faculty Opinions recommendation of Feasibility of whole-body diffusion-weighted MRI for detection of primary tumour, nodal and distant metastases in women with cancer during pregnancy: a pilot study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.732287009.793574701 ◽

2020 ◽

Author(s):

Teresa Woodruff

Keyword(s):

Pilot Study ◽

Primary Tumour ◽

Distant Metastases ◽

Whole Body ◽

Diffusion Weighted Mri ◽

Diffusion Weighted

Download Full-text

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.4_suppl.tps793 ◽

2020 ◽

Vol 38 (4_suppl) ◽

pp. TPS793-TPS793

Author(s):

Patrick Grierson ◽

Andrea Wang-Gillam ◽

Haeseong Park ◽

Katrina Pedersen ◽

Benjamin R. Tan ◽

...

Keyword(s):

Vitamin D ◽

Pilot Study ◽

Tumor Microenvironment ◽

Advanced Pancreatic Cancer ◽

Primary Objective ◽

High Serum ◽

Ductal Adenocarcinoma ◽

Combination Regimen ◽

Second Line ◽

Liposomal Irinotecan

TPS793 Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030, and is characterized by resistance to chemo- and radiotherapy and a highly fibrotic tumor microenvironment. Front-line therapies for advanced PDAC include FOLFIRINOX and gemcitabine/nab-paclitaxel with median overall survival ranging from 8.5 to 11 months. After progression on gemcitabine-containing therapy, 5-FU/LV/liposomal irinotecan is a standard second-line option, however outcomes are still poor. Retrospective studies demonstrate superior survival of advanced PDAC in patients with high serum levels of 25(OH) vitamin D. Notably, the PDAC tumor microenvironment is enriched in cancer-associated fibroblasts that favorably respond to vitamin D, prolonging survival in combination with chemotherapy in mouse models. Furthermore, vitamin D suppresses catabolism of irinotecan in gastrointestinal cancer cells, potentiating its efficacy. Therefore, we are conducing an investigator-initiated study of 5FU/LV/liposomal irinotecan with paricalcitol as second-line therapy in advanced PDAC. Methods: This is a pilot study of 5FU/LV/liposomal irinotecan combined with paricalcitol in patients with advanced PDAC progressed on gemcitabine-based therapy. All patients receive liposomal irinotecan, LV, 5-FU and paricalcitol. Liposomal irinotecan is given at 70 mg/m2 IV over 90 minutes, LV at 400 mg/m2 IV over 30 minutes, and 5-FU at 2400 mg/m2 continuous IV infusion over 46 hours, on Day 1 of each 14-day cycle. Paricalcitol IV infusion will precede the above, given according to assigned cohort (75 mcg weekly or 7 mcg/kg weekly). The primary objective of this study is to determine the tolerability between two different dose levels of paricalcitol added to the combination regimen of 5-FU/LV/liposomal irinotecan in patients with advanced PDAC. Secondary objectives are measures of efficacy (ORR, PFS, OS, CA19-9 biochemical response rate). Clinical trial information: NCT03883919.

Download Full-text